A. Ernest WhitonChief Financial OfficerZOLL Medical Corporation+1 (978) 421-9655
Diane EganZOLL Medical Corporation+1 (978) firstname.lastname@example.org
FOR IMMEDIATE RELEASE
September 5, 2006—CHELMSFORD, MASS.—ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and related software solutions, today reported that Our Lady of Mercy (OLM) Medical Center’s paramedic ambulance has deployed the ZOLL AutoPulse® Non-invasive Cardiac Support Pump. OLM EMS is the first 911 ambulance in New York City to deploy the device, which automates the performance of CPR chest compressions.
OLM EMS Emergency Services Director Michael Moculski noted in a recent New York Daily News article that the AutoPulse will “keep on doing CPR without stopping. There’s no fatigue for the rescue worker. It doesn’t have to stop to go up and down stairs.” Such continuous CPR performance can help improve blood flow to the heart and brain of a cardiac arrest victim.
The major emphasis of recently released American Heart Association 2005 Guidelines is performing effective, high-quality CPR. The 2005 Guidelines now recommend 30 compressions for every two rescue breaths—an increase from 15 compressions for every two breaths in the 2000 Guidelines. Furthermore, the Guidelines note that interrupting chest compressions can decrease the rate of survival from cardiac arrest.*
The AutoPulse is an automated, portable device with a simple, load-distributing LifeBand® that squeezes the entire chest in a consistent, uninterrupted “hands-free” manner, delivering maximum blood flow to the heart and brain.* Additionally, it offers the benefit of freeing up rescuers to focus on other life-saving interventions.
ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.
ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East, Asia, and Australia. For more information, visit www.zoll.com or call +1 (978) 421-9655.
Certain statements contained in this press release regarding matters that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, ZOLL’s ability to compete in the resuscitation business; acceptance of its recently launched products; changes in regulations affecting the healthcare industry; global economic conditions; and those other factors discussed in the section entitled “Risk Factors” in ZOLL’s Quarterly Report on Form 10-Q, which was filed with the SEC on August 11, 2006.
©2006 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AutoPulse, LifeBand, and ZOLL are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.
*Clinical data available upon request.